22nd Century Group, Inc. (XXII): Price and Financial Metrics


22nd Century Group, Inc. (XXII): $2.97

-0.13 (-4.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XXII to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

XXII POWR Grades


  • Momentum is the dimension where XXII ranks best; there it ranks ahead of 82.66% of US stocks.
  • The strongest trend for XXII is in Growth, which has been heading down over the past 48 weeks.
  • XXII's current lowest rank is in the Quality metric (where it is better than 1.29% of US stocks).

XXII Stock Summary

  • The ratio of debt to operating expenses for 22nd Century Group Inc is higher than it is for about just 15.67% of US stocks.
  • XXII's price/sales ratio is 16.93; that's higher than the P/S ratio of 88.76% of US stocks.
  • XXII's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.57% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to 22nd Century Group Inc are AXGN, AWH, BIOL, STIM, and XENT.
  • Visit XXII's SEC page to see the company's official filings. To visit the company's web site, go to www.xxiicentury.com.

XXII Valuation Summary

  • In comparison to the median Healthcare stock, XXII's price/earnings ratio is 180.27% lower, now standing at -29.3.
  • Over the past 129 months, XXII's price/sales ratio has gone NA NA.
  • Over the past 129 months, XXII's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XXII.

Stock Date P/S P/B P/E EV/EBIT
XXII 2021-08-31 19.5 6.7 -29.3 -29.5
XXII 2021-08-30 18.9 6.4 -28.4 -28.5
XXII 2021-08-27 21.7 7.4 -32.6 -32.7
XXII 2021-08-26 19.7 6.7 -29.6 -29.8
XXII 2021-08-25 20.0 6.8 -30.0 -30.2
XXII 2021-08-24 20.8 7.1 -31.3 -31.4

XXII Growth Metrics

  • The 4 year net income to common stockholders growth rate now stands at -180.44%.
  • Its 4 year revenue growth rate is now at 143.45%.
  • Its 3 year net income to common stockholders growth rate is now at -12.38%.
XXII's revenue has moved up $4,563,234 over the prior 33 months.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 29.795 -16.418 -19.829
2021-03-31 27.859 -14.87 -20.712
2020-12-31 28.111 -15.621 -19.711
2020-09-30 28.06499 -15.51382 -19.50443
2020-06-30 27.2169 -17.31555 -25.52915
2020-03-31 26.59688 -14.56757 -28.51383

XXII's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XXII has a Quality Grade of F, ranking ahead of 1.25% of graded US stocks.
  • XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
  • TPB, MO, and PM are the stocks whose asset turnover ratios are most correlated with XXII.

The table below shows XXII's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.448 0.073 -0.387
2021-03-31 0.485 0.065 -0.480
2020-12-31 0.479 0.051 -0.435
2020-09-30 0.446 0.038 -0.388
2020-06-30 0.425 0.025 -0.494
2020-03-31 0.400 0.015 -0.537

XXII Price Target

For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

XXII Stock Price Chart Interactive Chart >

Price chart for XXII

XXII Price/Volume Stats

Current price $2.97 52-week high $6.07
Prev. close $3.10 52-week low $0.58
Day low $2.90 Volume 1,215,800
Day high $3.07 Avg. volume 3,296,209
50-day MA $3.33 Dividend yield N/A
200-day MA $3.49 Market Cap 483.32M

22nd Century Group, Inc. (XXII) Company Bio


22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.


XXII Latest News Stream


Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream


Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22nd Century Group Inc that investors may wish to consider to help them evaluate XXII as an investment opportunity.

Top Pharmaceutical Stocks for Q4 2021

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.

Yahoo | September 14, 2021

Why 22nd Century Group Shares Are Trading Lower Today

22nd Century Group Inc (NASDAQ: XXII ) is trading lower Monday as investors react to the company''s announcement it will

Business Insider Markets | August 30, 2021

22nd Century Group Enters Global Specialty Hops Market

Geographic Expansion into Europe via the Netherlands Geographic Expansion into Europe via the Netherlands

Intrado Digital Media | August 30, 2021

22nd Century Group Announces Franchise In Global Specialty Hops Market

22nd Century Group Inc (NASDAQ: XXII ) announced its entry Monday into the global speciality hops market. What Happened: 22nd Century Group is a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science. The company says it will provide unique and significant competitive advantages to commercial partners in the sector . The addition of hops, a critical input for the $500-billion global Full story available on Benzinga.com

Benzinga | August 30, 2021

Arena Pharma, GrowGen & HEXO Among Top Cannabis Stock Movers On August 23, 2021

GAINERS: iAnthus Capital Hldgs (OTC: ITHUF ) shares closed up 35.27% at $0.28 with an estimated market cap of $48,870,997. Aleafia Health (OTC: ALEAF ) shares closed up 18.23% at $0.27 with an estimated market cap of $89,868,989. Item 9 Labs (OTC: INLB ) shares closed up 17.65% at $2 with an estimated market cap of $184,419,042. Tetra Bio Pharma (OTC: TBPMF ) shares closed up 10.78% at $0.24 with an estimated market cap of $96,530,242. Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 9.76% at $0.66 with an estimated market cap of $110,369,189. HEXO (NYSE: HEXO ) shares closed up 9.7% at $2.55 with an estimated market cap of $387,927,112. Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 9.19% at $51.21 with an estimated market cap of $3,127,620,843. Urban-gro (NASDAQ: UGRO )...

Benzinga | August 23, 2021

Read More 'XXII' Stories Here

XXII Price Returns

1-mo -18.85%
3-mo -37.74%
6-mo -2.94%
1-year 425.57%
3-year 8.79%
5-year 156.03%
YTD 35.00%
2020 100.00%
2019 -55.82%
2018 -11.07%
2017 156.88%
2016 -22.14%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8529 seconds.